×
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
NYSE:ENOV

Enovis Stock Forecast, Price & News

$55.61
-0.39 (-0.70%)
(As of 07/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$53.53
$56.15
50-Day Range
$55.00
$67.56
52-Week Range
$53.53
$164.01
Volume
534,235 shs
Average Volume
409,104 shs
Market Capitalization
$3.00 billion
P/E Ratio
42.13
Dividend Yield
N/A
Price Target
$67.33

Enovis MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
21.1% Upside
$67.33 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of Enovis in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
28.70%
From $2.30 to $2.96 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.79 out of 5 stars

Medical Sector

749th out of 1,426 stocks

Surgical Appliances & Supplies Industry

15th out of 30 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ENOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter.

Enovis logo

About Enovis (NYSE:ENOV) Stock

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.

ENOV Stock News Headlines

Enovis announces CFO transition
Enovis (NYSE:ENOV) Coverage Initiated at Argus
Loop Capital Reiterates "Buy" Rating for Enovis (NYSE:ENOV)
Enovis (NYSE:ENOV) Reaches New 52-Week Low at $54.85
Comparing Enovis (ENOV) & Its Peers
Reviewing Enovis (ENOV) and Its Peers
Enovis (ENOV) & The Competition Head-To-Head Contrast
Comparing Enovis (ENOV) & Its Rivals
Enovis Corporation
Head-To-Head Contrast: Enovis (ENOV) versus Its Competitors
Contrasting Enovis (ENOV) & Its Rivals
Enovis (ENOV) & The Competition Head to Head Survey
Enovis Corporation Tops Q1 EPS by 2c
See More Headlines

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Employees
16,200
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
7/05/2022
Next Earnings (Estimated)
7/27/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$67.33
High Stock Price Forecast
$73.00
Low Stock Price Forecast
$61.00
Forecasted Upside/Downside
+21.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33333333333333
Research Coverage
3 Analysts

Profitability

Net Income
$71.66 million
Pretax Margin
4.20%

Debt

Sales & Book Value

Annual Sales
$3.85 billion
Cash Flow
$11.47 per share
Book Value
$90.36 per share

Miscellaneous

Free Float
49,546,000
Market Cap
$3.00 billion
Optionable
Optionable
Beta
2.18














Enovis Frequently Asked Questions

Should I buy or sell Enovis stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Enovis stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENOV, but not buy additional shares or sell existing shares.
View analyst ratings for Enovis
or view top-rated stocks.

What is Enovis' stock price forecast for 2022?

3 equities research analysts have issued 1 year target prices for Enovis' stock. Their ENOV stock forecasts range from $61.00 to $73.00. On average, they expect Enovis' share price to reach $67.33 in the next twelve months. This suggests a possible upside of 21.1% from the stock's current price.
View analysts' price targets for Enovis
or view top-rated stocks among Wall Street analysts.

How has Enovis' stock price performed in 2022?

Enovis' stock was trading at $68.29 at the start of the year. Since then, ENOV stock has decreased by 18.6% and is now trading at $55.61.
View the best growth stocks for 2022 here
.

When is Enovis' next earnings date?

Enovis is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Enovis
.

How were Enovis' earnings last quarter?

Enovis Co. (NYSE:ENOV) announced its earnings results on Tuesday, May, 10th. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.03. The firm earned $375 million during the quarter, compared to analysts' expectations of $367.40 million. Enovis had a trailing twelve-month return on equity of 6.35% and a net margin of 1.77%. The company's quarterly revenue was up 20.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.32 EPS.
View Enovis' earnings history
.

What guidance has Enovis issued on next quarter's earnings?

Enovis issued an update on its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided earnings per share (EPS) guidance of $2.20-$2.40 for the period, compared to the consensus earnings per share estimate of $2.30. The company issued revenue guidance of -.

Who are Enovis' key executives?

Enovis' management team includes the following people:
  • Mr. Mitchell P. Rales, Co-Founder & Independent Chairman (Age 65, Pay $1)
  • Mr. Matthew L. Trerotola, CEO & Director (Age 55, Pay $3.48M)
  • Mr. Brady R. Shirley, Pres, COO & Director (Age 56, Pay $1.68M)
  • Mr. Christopher M. Hix, Exec. VP of Fin. & CFO (Age 60, Pay $1.39M)
  • Mr. Daniel A. Pryor, Exec. VP of Strategy & Bus. Devel. (Age 54, Pay $1.27M)
  • Mr. John Kleckner, Principal Accounting Officer (Age 45)
  • Mr. Michael S. Macek, VP of Fin. & Investor Relations (Age 50)
  • Mr. Bradley J. Tandy, Sr. VP & Gen. Counsel (Age 63)
  • Katie Sweet, VP of Corp. Communication
  • Ms. Patricia A. Lang, Sr. VP & Chief HR Officer (Age 63)

What is Enovis' stock symbol?

Enovis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENOV."

How do I buy shares of Enovis?

Shares of ENOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enovis' stock price today?

One share of ENOV stock can currently be purchased for approximately $55.61.

How much money does Enovis make?

Enovis (NYSE:ENOV) has a market capitalization of $3.00 billion and generates $3.85 billion in revenue each year. The company earns $71.66 million in net income (profit) each year or $1.3201 on an earnings per share basis.

How many employees does Enovis have?

Enovis employs 16,200 workers across the globe.

How can I contact Enovis?

Enovis' mailing address is 2711 Centerville Road Suite 400, Wilmington DE, 19808. The official website for Enovis is www.enovis.com. The company can be reached via phone at 302 252 9190, via email at investorrelations@colfaxcorp.com, or via fax at 301-323-9001.

This page (NYSE:ENOV) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.